NCT05085548: ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients who have not received at least one prior systemic treatment for advanced disease; Patients with leptomeningeal disease or with CNS metastases that are untreated or require treatment

Comments are closed.

Up ↑